## Highlights of This Issue 2213

### REVIEW

**New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects**

### THERAPEUTIC DISCOVERY

**Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells**
Nicole Berdelle, Teodora Nikolova, Steve Quiros, Thomas Efferth, and Bernd Kaina

**Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: In Vitro and Ex Vivo Studies in Humans**
Hyun-Seuk Moon, John P. Chamberland, Konstantinos Aronis, Sofia Tseleni-Balafouta, and Christos S. Mantzoros

**Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma**
Cheri Cloninger, Andrew Bernath, Tariq Bashir, Brent Holmes, Nicholas Artinian, Teresa Ruegg, Lauren Anderson, Janine Masri, Alan Lichtenstein, and Joseph Gera

**Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype**
Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair, Rachid Baz, Mark L. McLaughlin, Anne E. Cress, and Lori A. Hazlehurst

### PRECLINICAL DEVELOPMENT

**Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Ms1**
Keith D. Tardif, Aaron Rogers, Jared Cassiano, Bruce L. Roth, Daniel M. Cimbora, Rena McKinnon, Ashley Peterson, Thomas B. Douce, Rosann Robinson, Irene Dorweiler, Thaylon Davis, Mark A. Hess, Kirill Ostanin, Damon I. Papac, Vijay Baichwal, Ian McAlexander, J. Adam Willardsen, Michael Saunders, Hoarau Christophe, D. Vijay Kumar, Daniel A. Wettstein, Robert O. Carlson, and Brandi L. Williams

**Integrin α6high Cell Population Functions as an Initiator in Tumorigenesis and Relapse of Human Liposarcoma**
Lu Wang, Lingxian Wang, Yanhong Gu, Yongqian Shu, Yan Shen, and Qiang Xu

**Micelle-Encapsulated Thiostrepton as an Effective Nanomedicine for Inhibiting Tumor Growth and for Suppressing FOXM1 in Human Xenografts**
Ming Wang and Andrei L. Gartel

**Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth**
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
Yixian Zhang, Stephen Castaneda, Melissa Dumble, Maoliang Wang, Mary Mileski, Zhengxing Qu, Steven Kim, Victoria Shi, Patricia Kraft, Ying Gao, Jenny Pak, Puja Sapra, Raj Bandaru, Hong Zhao, Robert L. Vessella, Ivan D. Horak, and Lee M. Greenberger

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity
Deliang Cao, Amy Ziembas, James McCabe, Ruilan Yan, Laxiang Wan, Bradford Kim, Michael Gach, Stuart Flynn, and Giuseppe Pizzorno

The Bcl-2/Bcl-X<sub>j</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models
Jae-Ho Cheong, Eun Sung Park, Jiyoung Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Catherine Nguyen-Charles, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Muruli Ravoo, Vikas Kundra, Jaffer Ajani, Ju-Seog Lee, Wauk Ki Hong, and Gordon B. Mills

Vitamin E  δ-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-κB Activation in Pancreatic Cancer
Kazim Husain, Rony A. Francois, Teruo Yamauchi, Marta Perez, Said M. Sebti, and Mokeng P. Malafa

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
ABOUT THE COVER

Human lung microvascular cells cocultured with human diploid fibroblasts form extensive networks of tubules in response to VEGF that can be visualized by immunostaining for CD31, an endothelial cell marker. In the presence of cabozantinib (XL184), a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2, it was found that tubule formation was inhibited in the absence of cytotoxicity. Similarly, cabozantinib inhibited tubule formation in response to conditioned media derived from tumor cell cultures, suggesting that secreted tumor cell-derived proangiogenic growth factors are unable to circumvent inhibition of tubule formation by cabozantinib. For details, see article by Yakes and colleagues on page 2298.